Efficacy and safety of glutamine in treatment of severe sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001445

Enrollment

Unknown

Registered

2011-07-21

Start date

2011-04-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe sepsis

Interventions

therapy group:intravenous infusion of glutamine

blank group:NA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Systemic inflammation response syndrome associated with sepsis: T>38 degree C or 90bpm; RR>20bpm or PaO212.0*10^9/L or 10%; 2. Tissue hypoperfusion or organ dysfunction associated with sepsis: MAP1.5 or APTT>60s, or PLT70mmol/l3 Signed informed Consent

Exclusion criteria

Exclusion criteria: age<16 year; hypersensitive to glutamine; pregnant women

Design outcomes

Primary

Measure	Time frame
28-day survival rate;	—

Secondary

Measure	Time frame
length of stay in ICU;	—

Countries

China

Contacts

Public ContactJuan Chen

ayue97@hotmail.com+86 13600093819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026